Research Updates - Black TNBC Sanctuary

TNBC research has exploded over the past decade with major scientific advancements still on the horizon.

Research continues to focus on better understanding TNBC, improving early detection, and developing personalized treatment approaches based on genetic profiling and tumor characteristics.

There are a few major conferences that happen every year. The San Antonio Breast Cancer Symposium (SABCS) in early December, The American Society of Clinical Oncology (ASCO) Conference in early June, The American Association of Cancer Research (AACR) annual meeting in early April and their conference on the science of cancer health disparities in racial/ethnic minorities and the medically underserved in late September, and The European Society for Medical Oncology (ESMO) Breast Cancer conference in May. We’ll be bringing you any TNBC news from these major conferences throughout the year.

Check back regularly for updates about the latest TNBC research and news!

Updates

Experts Explore How to Treat Each Stage of Triple-negative Breast Cancer

How is each stage of TNBC treated? Can some patients with early-stage TNBC safely skip neoadjuvant chemotherapy? What are the risks and benefits of immunotherapy? What new treatment strategies are on the horizon for TNBC? A panel of breast cancer experts and a patient advocate discussed these questions and more at the San Antonio Breast Cancer Symposium 2025. Read the key takeaways from their discussion on Cancer Research Catalyst, the official blog of the American Association for Cancer Research (AACR).

Learn More

Your Guide to SABCS

SABCS is an international symposium that brings together the leading breast cancer researchers, scientists, doctors, and patient advocates in order to present the newest, cutting-edge research in breast cancer. Find out about the newest TNBC research presented at the most recent SABCS here.

Learn More

ASCENT-05 Trial for Triple-Negative Breast Cancer

The ASCENT-05 trial is comparing the effectiveness and safety of Trodelvy (chemical name: sacituzumab govitecan-hziy) in combination with Keytruda (chemical name: pembrolizumab) after surgery to either Keytruda alone or Keytruda plus Xeloda (chemical name: capecitabine) in people diagnosed with early-stage, triple-negative breast cancer that have residual disease after surgery.

Learn More

The Black Triple Negative Breast Cancer Sanctuary exists to be a haven in the storm for those impacted by Triple Negative Breast Cancer and their loved ones.

We provide access to personalized resources and clinical trials to aid in your fight against TNBC.

Learn about our mission

What questions can we help you answer? Please reach out to our team for any questions or inquiries.

Get In Touch

Connect with us on social

@TOUCHBBCA

@TNBC Foundation

@Nueva Vida

@AACR